Summary
Regeneron Pharmaceuticals, Inc. reported strong financial performance for the fiscal year ended December 31, 2021, with revenues more than doubling year-over-year to $16.1 billion and net income reaching $8.1 billion. This significant growth was largely driven by substantial sales of REGEN-COV, its antibody cocktail for COVID-19, which generated $7.6 billion in revenue. Key commercial products like EYLEA and Dupixent also demonstrated robust growth, with EYLEA sales reaching $9.4 billion and Dupixent sales hitting $6.2 billion globally (recorded by Sanofi). The company's diverse pipeline continues to advance, with multiple product candidates in late-stage clinical development across various therapeutic areas, including ophthalmology, immunology, inflammation, and oncology. Looking ahead, Regeneron is focused on expanding its marketed products' reach and advancing its pipeline. While REGEN-COV's utility has been impacted by the Omicron variant, the company is actively developing next-generation antibodies. The company maintains a strong financial position with significant cash reserves and has continued its share repurchase program. Investors should monitor the ongoing performance of EYLEA and Dupixent, the success of pipeline advancement, and potential impacts from regulatory changes and competition.
Financial Highlights
50 data points| Revenue | $16.07B |
| R&D Expenses | $2.86B |
| SG&A Expenses | $1.82B |
| Operating Expenses | $7.12B |
| Operating Income | $8.95B |
| Interest Expense | $57.30M |
| Net Income | $8.08B |
| EPS (Basic) | $76.40 |
| EPS (Diluted) | $71.97 |
| Shares Outstanding (Basic) | 105.70M |
| Shares Outstanding (Diluted) | 112.20M |
Key Highlights
- 1**Record Revenue Growth:** Total revenues surged to $16.1 billion for 2021, a significant increase from $8.5 billion in 2020, primarily driven by strong REGEN-COV sales.
- 2**Exceptional Profitability:** Net income reached $8.1 billion ($71.97 per diluted share) in 2021, a substantial increase from $3.5 billion ($30.52 per diluted share) in 2020.
- 3**REGEN-COV Dominance:** REGEN-COV was a major revenue contributor, generating $7.6 billion in global sales, though its effectiveness against the Omicron variant has limited its current utility.
- 4**Continued Strength in Core Products:** EYLEA sales reached $9.4 billion globally (with $5.8 billion in the U.S.), and Dupixent sales reached $6.2 billion globally (recorded by Sanofi), demonstrating sustained demand and market position.
- 5**Advancing Pipeline:** Regeneron continues to invest heavily in R&D, with numerous product candidates in various stages of clinical development, particularly in oncology and immunology.
- 6**Strong Balance Sheet and Shareholder Returns:** The company ended the year with over $12.5 billion in cash and marketable securities and repurchased $1.6 billion of common stock in 2021, with an additional $2.8 billion authorized for future repurchases.